Correction Notice: The role of long non-coding RNA BRE-AS1 in TNBC

Overview

This article has been retracted due to concerns about data integrity, specifically regarding similarities in figures that raised questions about the validity of the findings. The authors did not respond to inquiries from the publisher.

Background

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks three common receptors, making it challenging to treat. The identification of reliable biomarkers for prognosis and treatment response is critical in managing this aggressive cancer type.

Data Highlights

This article has been retracted and does not contain valid data.

Key Findings

• The article was retracted due to concerns about data integrity.
• Similarities were detected between multiple figures, raising questions about the validity of the findings.
• The authors did not respond to correspondence from the publisher regarding these concerns.

Clinical Implications

Healthcare professionals should be aware of the retraction.

Conclusion

The article has been retracted due to concerns about data integrity.

Related Resources & Content

1. BMC Cancer, 2021 -- Correction Notice: The role of long non-coding RNA BRE-AS1 in suppressing cancer cell growth
2. Frontiers in Oncology — Correction: SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
3. Frontiers in Oncology — Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker
4. Frontiers in Endocrinology — The role of LARP1 in breast cancer progression: from prognosis to immune microenvironment remodeling
5. Discovery of ASMTL-AS1 and LINC02604 Long Non-Coding RNAs as Potential Diagnostic Biomarkers for Colorectal Cancer
6. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer
7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer - PMC